Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex

World Journal of Urology

Volumn 18, Issue 2, 2000, Pages 152-156

  Hofîman, David M J ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 DIMYRISTYLOXYPROPYL)(DIMETHYL)(HYDROXYETHYL)AMMONIUM; (3-DIMYRISTYLOXYPROPYL)(DIMETHYL)(HYDROXYETHYL)AMMONIUM; INTERLEUKIN 2; LIPID; QUATERNARY AMMONIUM DERIVATIVE; RECOMBINANT PROTEIN;

AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; GENE TRANSFER; GENETICS; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; MALE; METASTASIS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMID; TRANSGENE;

AGED; BIOPSY; CARCINOMA, RENAL CELL; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIPIDS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; PLASMIDS; QUATERNARY AMMONIUM COMPOUNDS; RECOMBINANT PROTEINS; TRANSGENES;

EID: 0034169383     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450050189     Document Type: Article

References (43)

1. Abdel-Wahah Z. Li WP, Osanto S, Darrow TL, Messung J, Vervaert CE. Burrascano M, Barber J, Seigier HF (1994) Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol 159: 26-39
2. Addison CL. Braciak T, Ralston R, Muller WJ, Gauldie J. Graham FL (1995) Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sei USA 92: 8522-8526
3. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma. Cancer 80: 1198-1220
4. Cao X. Chen G, Zheng W, Tao Q. Y u Y, Ye T (1996) Enhanced efficacy of combination of the IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3: 421-426
5. Cassileth PA. Podack E. Shridar K, et al (1995) Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther 6: 369-383
6. Cordier L, Duffor MT. Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M. Haddada H (1995) Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2: 16-21
7. Economou JE, Hoban M. Ece JD. et al (1991) Production of tumor necrosis factor alpha and Interferon gamma in interleukin-2-lreated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother 34: 49-52
8. Egilmez NK, Cuenca R, Yokota SJ. Sorgi F. Bankert RB (1996) In vivo cytokine gene therapy of human tumor xenografts in SC1D mice by liposome-mediated DNA delivery. Gene Ther 3: 607-614
9. Ettinghausen SE. Moore JG, White DE. et al (1987) Hématologie effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654-1660
10. Farrar JJ, Benjamin WR, Hilftker ML, Howard M. Farrar WL, Fuller-Farrar J (1983) The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T-cell and antibody-forming B-cell responses. Immunol Rev 63: 139-166
11. Fearon ER, Pardoll DM, Itaya T. et al (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403
12. Feigner J, Kumar R, Sridhar CN, Wheeler CJ, Tsai Y, Border R. Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269: 2550-2561
13. Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161: 381-387
14. Figlin RA, Parker SE, Horton HM (1999) Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther 1: 271-278
15. Figlin RA, Parker SE, Horton HM (1999) Leuvectin Vical Inc. Curr Opin Oncol Endosc Metab Invest Drugs 1: 323-331
16. Figlin RA, Galanis E, Thompson J, Gillespie D (1999) Direct gene transfer of a plasmid encoding the IL-2 gene (Leuvectin) as treatment for patients with metastatic renal cell carcinoma (abstract 1662). Proc Am Soc Clin Oncol 18: 431A
17. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G (1997) High-dose aldesleukin in renal-cell carcinoma: long term survival update. Cancer J Sei Am 3: S70-S72
18. Fyfe G, Fisher RI, Rosenberg SA. et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696
19. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J (1999) Immunotherapy of advanced malignancy by direct gene transfer of an IL-2 DNA/DMRIE/DOPE lipid complex (Leuvectin): phase I/'II experience. J Clin Oncol (in press)
20. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224
21. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamanstein T, Blankenstein T (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sei USA 90: 2774-2778
22. Kammula US. White DE, Rosenberg SA (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805
23. Katsanis E, Orchard PJ, Bausero MA, Gordern KB, Mclvor RS, Blazer BR (1994) Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 15: 81-90
24. Kim TS, Cohen EP (1994) Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54: 2531-2535
25. Lee RE, Lotze MT, Skibber JM, et al (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7: 7-20
26. Lotze M, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant IL-2 in the
27. Onsanto S, Brouwenstyn N, Vaessen N, et al (1993) Immunization with interleukin-2 transfected melanoma cells: a phase I -II study in patients with metastatic melanoma. Hum Gene Ther 14: 323 333
28. Parker SE, Vahlsing HL, Serfilippi LM, Franklin CL, Doh SG, Gromkowski HS, et al (1995) Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Human Gene Ther 6: 575 590
29. Parker SE, Khatibi S, Margalith M, Anderson D, Yankauckas M, Gromkowski SH, Latimer T, Lew D, Marquet M, Manthorpe M, Hobart P, Hersh E, Stopeck A, Norman J (1996) Antitumor efficacy of plasmid DNA encoding the human IL-2 gene. Cancer Gene Ther 3: 175-185
30. Rosenberg SA, Lotze MT (1986) Cancer immunotherapy using interleukin-2-activated lymphocytes. Annu Rev Immunol 4' 681-709
31. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Lineham WM, Seipp ÇA, et al (1989) Experience with the use of highdose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-485
32. Saffran DC, Horton HM, Yankauckas M, Anderson D, Barnhart KM, Abai A, Hobart P, Manthorpe M, Norman JA, Parker SE (1998) Immunotherapy of established tumors in mice by intratumoral injections of IL-2 plasmid DNA: induction of CDS + T cell immunity. Cancer Gene Ther 5: 321330
33. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WD, Fair WR, Gilboa E (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54: 3516-3520
34. Sobol RE, Royston I, Fakhrai H, et al (1995) Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum Gene Ther 6: 195-204
35. Stopeck AT, Hersh EM, Brailey JL, Clark PR, Norman J, Parker SE (1998) Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther 5: 119-126
36. Sun T, Kim TS, Waltz MR, Cohen EP (1995) Interleukin-2secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Cancer Gene Ther 2: 183-190
37. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A, Glaspy J, Economou JS (1996) In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 3: 11-17
38. Vieweg J, Boczkowski D, Robertson KM, Edwards DW, Philip M, Philip R, Rudol T, Smiths C, Robertson C, Gilboa E (1995) Efficient gene transfer with adeno-associated virusbased plasmid complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55: 2366-2372
39. Vile RG, Hart IR (1994) Targeting of cytokine gene expression to malignant melanoma cells using tissue-specific promoter sequences. Ann Oncol 5 [Suppl 4]: S59-S66
40. Yang JC, Rosenberg SA (1997) An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sei Am 3 [Suppl]: S79-S84
41. Zatloukal K, Schneeberger A, Berger M, et al (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 154: 3406-3419
42. Zier KS, Gansbacher B (1996) IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. J Mol Med 74: 127-134
43. Zier K. Salvadori S, Cronin KC, Gansbacher B (1994) Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness. Cancer Gene Ther 1: 43-50